Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein

Abstract

Nucleocapsid p7 (NCp7) proteins of human immunodeficiency virus type 1 (HIV-1) contain two zinc binding domains of the sequence Cys-(X)2-Cys-(X)4-His-(X)4-Cys (CCHC)1,2. The spacing pattern and metal-chelating residues (3 Cys, 1 His) of these nucleocapsid CCHC zinc fingers are highly conserved among retroviruses1,3,4. These CCHC domains are required during both the early5,6 and late7,8 phases of retroviral replication, making them attractive targets for antiviral agents. Toward that end, we have identified a number of antiviral chemotypes that electrophilically attack the sulfur atoms of the zinc-coordinating cysteine residues of the domains9–14. Such nucleocapsid inhibitors were directly virucidal by preventing the initiation of reverse transcription15 and blocked formation of infectious virus from cells through modification of CCHC domains within Gag precursors16. Herein we report that azodicarbonamide (ADA) represents a new compound that inhibits HIV-1 and a broad range of retroviruses by targeting the the nucleocapsid CCHC domains. Vandevelde et al. 17 also recently disclosed that ADA inhibits HIV-1 infection via an unidentified mechanism and that ADA was introduced into Phase I/II clinical trials in Europe for advanced AIDS. These studies distinguish ADA as the first known nucleocapsid inhibitor to progress to human trials and provide a lead compound for drug optimization.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Henderson, L.E., Copeland, T.D., Sowder, R.C., Smythers, G.W. & Oroszlan, S. Primary structure of the low molecular weight nucleic acid-binding proteins of murine leukemia viruses. J. Biol. Chem. 256, 8400–8406 (1981).

    CAS  PubMed  Google Scholar 

  2. Berg, J.M. Potential metal-binding domains in nucleic acid binding proteins. Science 232, 485–487 (1986).

    Article  CAS  Google Scholar 

  3. South, T.L. et al. The nucleocapsid protein isolated from HIV-1 particles binds zinc and forms retroviral-type zinc fingers. Biochem. 29, 7786–7789 (1990).

    Article  CAS  Google Scholar 

  4. South, T.L. & Summers, M.F. Zinc fingers. Adv. Inorg. Biochem. Ser. 8, 199–248 (1990).

    CAS  Google Scholar 

  5. Darlix, J.-L., Vincent, A., Gabus, C., De Rocquigny, H., & Roques, B. . Transactivation of the 5' to 3' viral DNA strand transfer by nucleocapsid protein during reverse transcription of HIV-1 RNA. C. R. Acad. Sci. III 316, 763–771 (1993).

    CAS  PubMed  Google Scholar 

  6. You, J.C. & McHenery, C.S. Human immunodeficiency virus nucleocapsid protein accelerates strand transfer of the terminally redundant sequences involved in reverse transcription. J. Biol. Chem. 269, 31491–31495 (1994).

    CAS  PubMed  Google Scholar 

  7. Aldovini, A. & Young, R.A. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of non infectious virus. J. Virol. 64, 1920–1926 (1990).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Gorelick, R.J. et al. Genetic analysis of the zinc finger in the Moloney murine leukemia virus nucleocapsid domain: Replacement of zinc-coordinating residues with other zinc-coordinating residues yields noninfectious particles containing genomic RNA. J. Virol. 70, 2593–2597 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Rice, W.G. et al. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature 361, 473–475 (1993).

    Article  CAS  Google Scholar 

  10. Rice, W.G. et al. The site of action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc Natl. Acad. Sci. USA 90, 9721–9724 (1993).

    Article  CAS  Google Scholar 

  11. Rice, W.G. et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270, 1194–1197 (1995).

    Article  CAS  Google Scholar 

  12. Rice, W.G. & Turpin, J.A. Virus-encoded zinc fingers as targets for antiviral chemotherapy. Reviews Med. Virol. 6, 187–199 (1996).

    Article  CAS  Google Scholar 

  13. Rice, W.G. et al. Inhibition of multiple phases of HIV-1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents. Chemother. 41, 419–426 (1997).

    Article  CAS  Google Scholar 

  14. Rice, W.G. et al. Evaluation of selected chemotypes in coupled Cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. J. Med. Chem. 39, 3606–3616 (1996).

    Article  CAS  Google Scholar 

  15. Turpin, J.A. et al. Reverse transcription of human immunodeficiency virus type 1 is blocked by retroviral zinc finger inhibitors. Antiviral. Chem. Chemother. 8, 60–69 (1997).

    Article  CAS  Google Scholar 

  16. Turpin, J.A. et al. Inhibitors of HIV-1 zinc fingers prevent normal processing of Gag precursors and result in the release of noninfectious virus particles. J. Virol. 70, 6180–6189 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Vandevelde, M. et al. ADA, a potential anti-HIV drug. AIDS Res. Hum. Retro. 12, 567–568 (1996).

    Article  CAS  Google Scholar 

  18. South, T.L., Kim, B. & Summers, M.F. 113Cd NMR studies of a 1:1 Cd adduct with an 18-residue zinc finger peptide from HIV-1 nucleic acid binding protein, p7. J. Am. Chem. Soc. 111, 395–397 (1989).

    Article  CAS  Google Scholar 

  19. Wallqvist, A. & Covell, D.G. Docking enzyme-inhibitor complexes using a preference based free-energy surface. Proteins 25, 403–419 (1996).

    Article  CAS  Google Scholar 

  20. Bushman, F.D. & Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: Specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 88, 1339–1343 (1991).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rice, W., Turpin, J., Huang, M. et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 3, 341–345 (1997). https://doi.org/10.1038/nm0397-341

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0397-341

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing